Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 9/20 | 1.00 |
| ▸ | MASP2 | O00187 | 1/20 | 1.00 |
| ▸ | CMA1 | P23946 | 3/20 | 0.89 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211813 | 1.00 | CTSG (1.00) | CTSGMASP2CMA1ACP3ABL1 | |
| SCHEMBL1260969 | 0.94 | CTSG (1.00) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL30583367 | 0.94 | CTSG (1.00) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL30355342 | 0.94 | CTSG (1.00) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL1614372 | 0.91 | CTSG (0.91) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL1614762 | 0.90 | CTSG (0.82) | CTSGMASP2CMA1ACP3PTGDR2 | |
| SCHEMBL1614715 | 0.90 | CTSG (0.89) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL28330371 | 0.90 | CTSG (0.81) | CTSGMASP2CMA1ACP3ABL1 | |
| SCHEMBL10146840 | 0.89 | CTSG (0.90) | CTSGMASP2CMA1ACP3NPC1 | |
| SCHEMBL4455609 | 0.89 | CTSG (0.90) | CTSGMASP2CMA1ACP3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304430-B2 | Phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-20110086819-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | GRECO MICHAEL N | 2011-04-14 | — | — | US | claimed |
| EP-1438316-B1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO MCNEIL PHARM INC (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1438316-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | claimed |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | GRECO MICHAEL N (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003035654-A1 | PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20230364037-A1 | CANCER THERAPEUTIC | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2023-11-16 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200197335-A1 | CANCER THERAPEUTIC | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2020-06-25 | — | — | US | disclosed |
| WO-2020027665-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR CANCER THERAPY | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2020-02-06 | — | — | WO | disclosed |
| US-20170360829-A1 | TREATMENT OF VASCULAR ANOMALIES | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-12-21 | — | — | US | disclosed |
| US-20170234884-A1 | CANCER DIAGNOSIS AND THERAPY | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-08-17 | — | — | US | disclosed |
| WO-2017131534-A1 | TREATMENT OF VASCULAR ANOMALIES | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-08-03 | — | — | WO | disclosed |
| EP-3180000-A1 | CANCER DIAGNOSIS AND THERAPY | Gillies Mcindoe Research Institute (NZ) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017095236-A1 | TREATMENT OF FIBROTIC CONDITIONS | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2017-06-08 | — | — | WO | disclosed |
| WO-2016024870-A1 | CANCER DIAGNOSIS AND THERAPY | GILLIES MCINDOE RESEARCH INSTITUTE (NZ) | 2016-02-18 | — | — | WO | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082544-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CTSG 787/4885MASP2 1/4885CMA1 887/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSG 787/4885MASP2 1/4885CMA1 887/4885 |
| US-20110086819-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
| US-20030195172-A1 | Novel phosphonic acid compounds as inhibitors of serine proteases | HPN, PRSS1, SERPINB1 | CTSG 251/4885MASP2 31/4885CMA1 137/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CTSG 1249/4885MASP2 3443/4885CMA1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.